Ultragenyx's bone disease drug fails late-stage trials
29/12/2025 13:33
Dec 29 (Reuters) - Ultragenyx Pharmaceutical RARE.O said on Monday that its experimental drug for a type of genetic bone disease did not meet the main goal in late-stage studies. (Reporting by Sneha S K; Editing by Shailesh Kuber) ((Sneha.SK@thomsonreuters.com;))
Recent news on Ultragenyx Pharmaceutical
See all newsBrief: Ultragenyx Pharmaceutical Enters Settlement Agreement With Navinta On Dojolvi Patent Litigation - SEC Filing
Ultragenyx gains on $210 million US FDA voucher sale
Brief: Ultragenyx Pharmaceutical - Under Deal With U.S. Department Of Health Co To Pay 20% Of Prv Sale Proceeds To Nih
Brief: Ultragenyx Enters Into Agreement To Sell Rare Pediatric Disease Priority Review Voucher For $210 Million
U.S. STOCKS ON THE MOVE-CoreWeave, StubHub, Ultragenyx